Company intelligence / Profile preview

Channel-Markers Medical

Raleigh, North Carolina, United States

Ownership: Private
Development stage: Other

Overview

Channel-Markers Medical commercially markets injectable hyaluronic acid therapies (TriVisc and GenVisc 850) indicated for osteoarthritis knee pain, having acquired these approved, marketed products from Avanos Medical in July 2025. Clinical use and safety profiles are well established.

Therapeutic areas: Rheumatology
Modalities: BiologicDevice
Industry: Therapeutic Medical Devices

Partnerships

Avanos Medical (product acquisition, 2025)

Beyond the preview

Go deeper on Channel-Markers Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Channel-Markers Medical.

Explore the full profile